🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  2. Bivalent killed oral cholera vaccine

    International Peace Maternity and Child Health Hospital

    Cholera

    phase 2 mab active

    1 trial

  3. Bleomycin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphatic Malformation

    phase 2 small molecule active

    1 trial

  4. Blinatumomab

    The First People's Hospital of Lianyungang

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  5. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  6. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Plasma Cell Leukemia

    phase 2 small molecule active

    1 trial

  7. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 small molecule active

    1 trial

  8. Bosentan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 2 small molecule active

    1 trial

  9. Bovine colostrum

    Hospital Authority, Hong Kong

    Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54

    phase 2 other completed

    1 trial

  10. Bozitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    NSCLC

    phase 2 small molecule active

    1 trial

  11. Bronchial basal cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchiectasis

    phase 2 mab active

    1 trial

  12. Bronchial basal cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Obstructive Pulmonary Disease

    phase 2 mab completed

    1 trial

  13. Bu-Yang-Huan-Wu Tang

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ischemic Stroke

    phase 2 small molecule active

    1 trial

  14. Busulfan

    Children's Hospital of Fudan University

    Juvenile Myelomonocytic Leukemia

    phase 2 small molecule completed

    1 trial

  15. C-CAR088

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Multiple Myeloma

    phase 2 small molecule active

    2 trials

  16. C225 (cetuximab)

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  17. CALCIUM FOLINATE, ivonescimab, CALCIUM LEVOFOLINATE, OXALIPLATIN, FLUOROURACIL

    Ningbo Cancer Hospital

    Advanced biliary tract cancer (BTC)

    phase 2 small molecule active

    1 trial

  18. CAPECITABINE, CAPECITABINE, NUBEQA 300 mg film-coated tablets

    Ningbo Cancer Hospital

    Triple-negative androgen receptor positive (molecular apocrine-like HER2-negative subtype) locally recurrent (unresectable) or metastatic breast cancer.

    phase 2 small molecule active

    1 trial

  19. CAPECITABINE, CAPECITABINE, PEMBROLIZUMAB

    Ningbo Cancer Hospital

    Triple Negative Breast Cancer with residual disease after neoadjuvant chemo-immunotherapy.

    phase 2 small molecule active

    1 trial

  20. CAPECITABINE, Lonsurf 15 mg/6.14 mg film-coated tablets, FOLINIC ACID, FLUOROURACIL, OXALIPLATIN, NIVOLUMAB, Lonsurf 20 mg/8.19 mg film-coated tablets, LEVOLEUCOVORIN

    Ningbo Cancer Hospital

    Patients with HER 2 negative locally advanced, recurrent or metastatic gastric, oesophagus or gastroesophageal junction adenocarcinoma

    phase 2 small molecule active

    1 trial

  21. CAPECITABINE, OXALIPLATIN, FLUOROURACIL, CAPECITABINE, FOLINIC ACID

    Ningbo Cancer Hospital

    Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication

    phase 2 small molecule active

    1 trial

  22. CAR T-cell therapy

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia With Failed Remission

    phase 2 mab active

    1 trial

  23. CAR-BCMA T Cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  24. CAR-T

    The First People's Hospital of Lianyungang

    Leukemia, Lymphocytic, Chronic, B-Cell

    phase 2 mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources